GLP1R and metabolic dysfunction-associated steatohepatitis: Figure 3 shows the forest plot and pooled estimates of the effect of GLP-1 RAs (n = 2 placebo-controlled RCTs included using either liraglutide 1.8 mg/day or semaglutide at a dose of 0.1 mg, 0.2 mg or 0.4 mg/day subcutaneously) on histologic resolution of NASH with no worsening of liver fibrosis (panel A), and improvement in liver fibrosis stage without worsening of NASH (panel B).